Given that USP11 appears to play a functional role in EGFR- or TLR-driven CRC progression, we investigated whether USP11 could be a viable therapeutic target for inhibiting EGFR- or TLR-driven CRC tumor growth. This evidence concerns the gene EGFR and neoplasm.